Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles.

By Felix Kratz. Journal of Controlled Release, 2008

2,065 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. (2014, background): “Nanoparticles of cross-linked human serum albumin (HSA) have shown good biocompatibility and have been used for drug delivery purposes [105,106].”
Unraveling the mysteries of serum albumin—more than just a serum protein (2014, background): “Various drug delivery systems with albumin have been developed including albumin nanoparticles, drug albumin conjugates, albumin-binding drug derivatives and prodrugs (for reviews see Kratz, 2008, 2010).”
The journey of a drug-carrier in the body: an anatomo-physiological perspective. (2012, background): “These range from albumin-drug conjugates [43] to systems scavenging the protein in vivo through high-affinity binding [44] or in situ covalent bond formation on the reactive functions of albumin [36,42].”
Albumin-based drug delivery: harnessing nature to cure disease (2016, background): “hydrazone linker that is thought to be cleaved upon delivery at tumour sites due to an acidic extracellular environment or inside endosomes or lysosomes after cellular uptake [11, 109].”
On the nature of biomaterials. (2009, methodology): “Drug conjugates have been prepared with N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer or polyethylene glycol conjugated with doxorubicin or paclitaxel, as has an albumin-binding doxorubicin conjugate [35].”